REFRACTORY MISMATCH REPAIR PROFICIENT COLORECTAL CARCINOMA

Clinical trials for REFRACTORY MISMATCH REPAIR PROFICIENT COLORECTAL CARCINOMA explained in plain language.

Never miss a new study

Get alerted when new REFRACTORY MISMATCH REPAIR PROFICIENT COLORECTAL CARCINOMA trials appear

Sign up with your email to follow new studies for REFRACTORY MISMATCH REPAIR PROFICIENT COLORECTAL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1

Experimental drug aims to target Tough-to-Treat colon cancer

Disease control Terminated

This study aimed to test an experimental drug called CBX-12 for people with advanced colorectal cancer that had spread and was no longer responding to standard chemotherapy. The drug was designed to deliver a cancer-killing agent directly into tumor cells. The trial was withdrawn…

Matched conditions: REFRACTORY MISMATCH REPAIR PROFICIENT COLORECTAL CARCINOMA

Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control

Last updated Mar 31, 2026 12:10 UTC

REFRACTORY MISMATCH REPAIR PROFICIENT COLORECTAL CARCINOMA

Get alerted when new REFRACTORY MISMATCH REPAIR PROFICIENT COLORECTAL CARCINOMA trials appear

Experimental drug aims to target Tough-to-Treat colon cancer